Clinical Applications Using PCT

Clinical Applications and Strategies Using Procalcitonin (PCT) to Improve Patient Outcomes


speaker_profile_image_dd4dfb88d50d0b0c471227e24c9efdce0a6601cd_697_MOD-2-120-120-center.jpgEric Gluck, M.D., J.D., FCCP, FCCM

Director of Critical Services Swedish Covenant Hospital



Over 1.6 million people are diagnosed with sepsis in the U.S. each year1 and sepsis is the #1 cost of hospitalization (over $24 billion each year)1. Having a biomarker that can quickly identify sepsis is critical because mortality increases 8% every hour that treatment is delayed1.

Procalcitonin (PCT) helps determine if the patient has a bacterial infection (sepsis), the severity of the infection and is the patient responding to therapy2. PCT is a more accurate diagnostic parameter for sepsis and a better predictor of mortality and a more reliable marker than other biomarkers3. PCT also provides clinicians a mechanism for antibiotic stewardship2.


  1. Sepsis Alliance Website:
  2. Thermo Scientific B-R-A-H-M-S PCT Improving infection management.
  3. Shiferaw, et al. The Role of Procalcitonin as a Biomarker in Sepsis. J Infect Dis Epidemiology. 2016;2:006 Vol 2.


Learning Objectives
  • Understand the clinical utility of PCT.
  • Incorporate PCT protocols as part of sepsis management.
  • Demonstrate the impact PCT can have on clinical and financial outcomes


View Webinar (75:22 minutes)
Keeping Pace with Viral Evolution
June 23, 2015


John R. Hackett Jr., Ph.D., Abbott Diagnostics

Main Content:

Transforming Infectious Disease Diagnostics by Global Surveillance and Novel Technology

Accurate diagnosis of infectious agents is an important task of laboratories everywhere in the world. As some viruses - especially those with a reverse transcription step in their life cycle - are prone to rapid changes, there is a constant challenge for diagnostic assays to keep pace with viral evolution. Viral vigilance can only be achieved by a comprehensive surveillance system that Abbott has established more than 20 years ago and constantly expanded since. After this workshop, participants will understand the need for a global viral surveillance system and appreciate its impact on the development and performance of diagnostic assays. 

View Webinar

Three Decades of HIV Detection
December 07, 2015


Marc Van Ranst, Professor of Virology and Epidemiology, Chairman, Department of Microbiology and Immunology, Director, Clinical and Epidemiological Virology Unit, Rega Institute for Medical Research University of Leuven, Head of the Laboratory Medicine Department University Hospitals Leuven, Belgium.

Main Content:

The HIV and AIDS pandemic ranks among the most devastating in recorded history. Substantial research efforts over the past 30 years have led to novel discoveries with respect to the virus, its detection, and in the development of robust antiviral drugs that have transformed both the treatment and prevention. 

This webinar provides a historical perspective of the major milestones in HIV science, highlighting how they evolved with time and how translational research has affected treatment and prevention of HIV. The webinar also discusses current research directions including the scientific challenges ahead for a cure for HIV and the active efforts across the globe toward ending the AIDS epidemic by 2030.

About Dr. Marc Van Ranst

Dr. Marc Van Ranst is a Belgian virologist and epidemiologist at the University of Leuven and the Rega Institute for Medical Research in Leuven, Belgium. He is chairman of the department of Microbiology and Immunology, and director of the clinical department of laboratory medicine. His research laboratory studies the molecular evolution of DNA and RNA viruses. He teaches virology at the University of Leuven and the University College of Leuven-Limburg, and bioinformatics at Charles University in Prague, Czech Republic. He has published over 340 scientific papers in peer-reviewed and Medline-indexed journals and contributed chapters to eight books on viral molecular evolution and bioinformatics.

Van Ranst obtained a BA in Medicine at the University of Hasselt in 1986, and graduated magna cum laude as medical doctor at the University of Leuven in 1990. During his PhD years he studies at Albert Einstein College of Medicine in New York, and he received his PhD in Microbiology and Immunology in 1994. In 2004, he was awarded the European Clinical Virology Heine-Medin award of the European Society for Clinical Virology. In 2005 he received a doctor honoris causa degree at the University of Kalmar in Sweden. He was appointed by the Belgian federal government as interministerial commissioner to guide the crisis management during the Mexican flu pandemic in 2009-2010.


Learning Objectives:

  • Understand the complex zoonotic origins of HIV, the early epidemic spread of HIV, and the discovery of HIV
  • Learn about the various generations of HIV immunoassays
  • Understand the evolution of HIV therapeutic strategies
  • Learn about the ambitious goals of UNAIDS to end the AIDS epidemic by 2030

View Webinar


additional webinars

cardiac webinars

View webinars on Cardiac.


diabetes webinars

View webinars on Diabetes.


You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. The website that you have requested also may not be optimised for your screen size.

Do you wish to continue and exit this website?

Yes No

You are about to enter an Abbott country or region specific website.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.

Do you wish to continue and enter this website?

Yes No


Content is not under the control of

Yes No